Advertisement

The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications

  • Hongmei Zheng
  • Yuting Zhan
  • Sile Liu
  • Junmi Lu
  • Jiadi Luo
  • Juan Feng
  • Songqing Fan
Open Access
Review
  • 634 Downloads

Abstract

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, and it is one of the leading causes of cancer death in both men and women worldwide due to diagnosis in the advanced stage, rapid metastasis, and recurrence. At present, precision molecular targeted therapeutics directed toward NSCLC driven genes has made great progress and significantly improved the overall survival of patients with NSCLC, but can easily lead to acquired drug resistance. New methods are needed to develop real-time monitoring of drug efficacy and drug resistance, such as new molecular markers for more effective early detection and prediction of prognosis. Exosomes are nano-sized extracellular vesicles, containing proteins, nucleic acids and lipids, which are secreted by various cells, and they play an important role in the development of lung cancer by controlling a wide range of pathways. Tumor-derived exosomes are of great significance for guiding the targeted therapy of NSCLC and exosomes themselves can be a target for treatment. In this review, we describe the potential roles of tumor-derived exosomes and their clinical significance in NSCLC.

Keywords

NSCLC Tumor-derived exosomes Clinical implications Targeted therapy 

Abbreviations

ADAPT

Adaptive dialysis-like affinity platform technology

AKT

Protein Kinase B

ALK

Anaplastic lymphoma kinase

CAFs

Cancer-associated fibroblasts

EGFR

Epidermal growth factor receptor

EMT

Epithelial–mesenchymal-transition

ERK

Extracellular signal-regulated kinase

GSK3β

Glycogen synthase kinase 3β

GTPase

Guanosine triphosphatase

HSP72

Heat shock protein 72

IL-10

Interleukin-10

KRAS

Kirsten rat sarcoma viral oncogene

LKB1

Liver kinase B1

MDR

Multi-drug resistant

MDR-ABC

MDR-associated ATP-binding cassette transporter

MDSCs

Myeloid-derived suppressor cells

MSCs

Mesenchymal stem cells

MVBs

Multivesicular bodies

NF-kB

Nuclear factor kappa B

NSCLC

Non-small cell lung cancer

OS

Overall survival

PFS

Progression free survival

PPIs

Proton pump inhibitors

SCLC

Small-cell lung cancer

STAT3

Signal transducers and activators of transcription 3

TD-exosomes

Tumor-derived exosomes

TGF-β

Transforming growth factor β

TGF-β1

Transforming growth factor β1

TKIs

Tyrosine kinase inhibitors

TLR

Toll-like receptor

TME

Tumor microenvironment

Treg

Regulatory T cell

VEGF

Vascular endothelial growth factor

ZO-1

Zonula occludens-1

Background

Lung cancer is one of the leading causes of cancer-related death both in men and women [1] and remains the most frequently diagnosed cancer in the world [2], which is classified into two histological subtypes: non-small cell lung cancer(NSCLC)accounting for 85% and small-cell lung cancer (SCLC) accounting for the remaining 15% [3]. Only 17.7% of the patients live over 5 years after being diagnosed with lung cancer [4]. The standard treatment of NSCLC is curative surgical resection, combined with or without chemoradiotherapy for the patients with early-stage including stage I, II and a part of stage III [5, 6]. However, most patients with NSCLC are diagnosed in the advanced stage [7], which makes the cancer difficult to surgically resect and increases the rate of postoperative recurrence, while the effect of radiotherapy and chemotherapy has plateaued [8]. On the other hand, treatment of NSCLC is evolving from the use of cytotoxic chemotherapy to precision treatment based on changes in molecular and gene levels [9], which inevitably leads to drug resistance sooner or later. In the past, the golden standard of the patients’ diagnosis and gene mutations detection is tissue biopsy, which limits the assessment of lung cancer development and prognosis due to tumor heterogeneity and evolution [10]. Liquid biopsy is typically used to separate and analyze circulating free DNA and RNA from the blood of cancer patients, or other body fluids, which has potential advantages, such as real-time monitoring of treatment response, rapid and accurate identification of drug resistance genes, identification of minimal residual disease and prediction of prognosis [10, 11]. Exosomes are nano-sized extracellular vesicles, containing proteins, nucleic acids and lipids and the encapsulated contents in exosomes can escape from the degradation. Exosomes play an important role in cell-to-cell communication, tumor progression and drug resistance and have excellent prospects in liquid biopsy [12, 13, 14]. In this review, we discuss the close relationship between tumor-derived exosomes and NSCLC, and the application of tumor-derived exosomes in the targeted therapy for NSCLC.

Exosomes and tumor-derived exosomes

The diameter of exosomes which was first reported in the process of sheep reticulocytes maturation ranged from 40 to 100 nm, showing a characteristic cup-shaped morphology (after negative staining) or round well-delimited vesicles observed by transmission and cryo-electron microscope [15, 16]. Exosomes are small vesicles of endosomes that can be released by many cell types, such as reticulocytes [16], dendritic cells [17], lymphocytes [18, 19] and cancer cells [20]. Furthermore, exosomes have been successfully purified from many body fluids such as blood, urine, pleural effusions, ascites and broncoalveolar fluid [21]. Also, exosomes can transfer information, including DNA, RNA and proteins, to the receptor cells through fusion with the plasma membrane, endocytosis by phagocytic mechanism or receptor-ligand interaction with the cell [22] and have the heterogeneous biological behaviors due to their different secretory cell types with diverse cell status [23], thus participating in different physiological and pathological processes. Rab GTPases, including Rab27a and Rab27b, are the key regulators of exosomes secretion and Rab27 is closely related to the occurrence and the development of tumor, which indicates the role of exosomes secretion in tumor biology [24]. (These are summarized in Fig. 1).
Fig. 1

The biology of exosomes. Exosomes are some vesicles ranged from 40 to 100 nm, which can be released by many cells and purified from many body fluids. Exosomes can transfer information to the receptor cells through fusion with the plasma membrane, endocytosis by phagocytic mechanism or receptor-ligand interaction with the cell

The immunological activities of exosomes affect the mechanisms of immunoregulation including immune activation, antigen expression regulation, intercellular communication, immunization surveillance, and immunosuppression [25]. Tumor-derived exosomes which carry tumor-associated antigens can interfere with anti-tumor immunotherapies [26]. It has been reported that about 2000 trillion exosomes can be detected in normal human blood versus 4000 trillion exosomes in the blood of cancer patients [27], which indicates that tumor cells produce more exosomes than their normal counterparts and can be a useful diagnostic biomarker [28]. Tumor-derived exosomes are believed to be important mediators of intercellular signaling and epithelial–mesenchymal transition (EMT), which transforms cancer cells into more aggressive phenotype, and contributes to the tropism of metastatic disease in specific cancer types with pre-metastatic niche [29]. Azmi et al. found tumor cells exposed to hypoxia secreted exosomes which had enhanced potential of angiogenesis and metastasis, suggesting that tumor cells adapt themselves to the hypoxic microenvironment by secreting exosomes, so as to stimulate angiogenesis or create a more favorable tumor microenvironment to promote tumor metastasis [30]. Furthermore, tumor-derived exosomes are of crucial importance in tumor growth and drug resistance, as they transfer nucleic acids and oncogenic proteins to the tumor cells, which indicates tumor-derived exosomes and their contents may be of potential value in the diagnosis, prognosis, prediction of treatment response and targeted therapy [31]. Due to the importance of tumor-derived exosomes, the methods to detect exosomes including isolation purification and analysis require further development (These methods are summarized in Table 1).
Table 1

Detection methods of exosomes

Contents

Methods

References

Isolation and purification

Ultracentrifugation

Density gradients centrifugation

Immunobeads

Size exclusion chromatography

Spin column-based methods

[127, 128, 129, 130, 131]

Analysis of size and shape

TEM

[132]

Analysis of size distribution and concentration

Nanoparticle Tracking Analysis

FAVS

[133, 134, 135]

Analysis of proteins

Mass spectrometry, Western-blot

SDS-PAGE

[136, 137]

Analysis of RNA

NGS, Microarray, RT-PCR

[138, 139, 140]

Roles of Tumor-derived exosomes in the NSCLC

The formation and development of NSCLC is influenced by many factors and mechanisms, which is a long-term and complex process. Exosomes secreted by lung cancer cells play a vital role in this process as mediators of intercellular communication. (These roles are summarized in Fig. 2).
Fig. 2

Roles of Tumor-derived exosomes in the NSCLC. Tumor-derived exosomes play a vital role in tumor growth and progression, invasion and metastasis, targeted drug resistance, and can also be used as biomarkers for early diagnosis, prediction of treatment response and prognosis

Tumor-derived exosomes in the growth and progression of NSCLC

It has been shown that cancer-associated fibroblasts (CAFs) in the tumor microenvironment can secrete exosomes containing lipids, amino acids, and TCA-cycle intermediates which can promote tumor growth under nutrient-stressed or nutrient-deprivation conditions [32]. Angiogenesis is also vital for tumor growth since tumor vessels are the important sources of nutrient substances in the tumor cells [33]. Tumor-derived exosomes can accelerate angiogenesis and tumor growth in a TGFβ1 (transforming growth factor β1)-dependent pathway to stimulate fibroblasts to differentiate into tumor-promoting stromal myofibroblasts [34]. Exosomal miR-23a from hypoxic lung cancer cells can increase angiogenesis and vascular permeability by targeting tight junction protein ZO-1(zonula occludens-1) and prolyl hydroxylase [35]. STAT3-regulated exosomal miR-21 enhances the level of vascular endothelial growth factor (VEGF), thereby promoting tumor angiogenesis and inducing malignant transformation of bronchial epithelial cells [36]. Exosomal miR-210 from lung cancer regulates the level of tyrosine receptor kinase A3 (ephrin A3) in matrix cells and promotes tumor angiogenesis to maintain the growth of tumor cells [37]. All of these indicated that tumor-derived exosomes can promote the growth and progression of NSCLC by angiogenesis. Lung cancer cell-derived exosomes can also affect the progression of lung cancer by affecting the physiological functions of other cells in the surrounding tissues and microenvironment. Mesenchymal stem cell (MSC) is an important one among these cells, which can be transformed into a pro-inflammatory phenotype via NFκB-TLR signaling pathway regulated by lung cancer cell-derived exosomes, thus promoting the growth of lung cancer [38]. Furthermore, lung cancer cell-derived exosomes can indirectly regulate the progression of tumor by affecting the function of immune cells in the tumor microenvironment. Tumor-derived exosomes can help with immune escape by transferring specific proteins and RNA into the receptor cells [39] and promote tumor progression by reprogramming functions of immune cells [26]. Lung cancer cell-derived exosomes containing the epidermal growth factor receptor (EGFR) can induce tolerogenic dendritic cells and tumor antigen-specific regulatory T cells (Treg) which can inhibit the function of CD positive T cells with anti-tumor function and promote the growth of lung cancer [40, 41]. Lung cancer cell-derived exosomes containing HSP72 (heat shock protein 72) can activate the STAT3 signaling pathway to mediate the immunosuppressive effect of MDSCs (myeloid-derived suppressor cells) and thereby suppress T cell activation [42, 43]. In conclusion, these studies revealed that tumor-derived exosomes could play an important role in the growth and progression of NSCLC with different contents and provide a novel future for the therapy of NSCLC, which should be further researched.

Tumor-derived exosomes in the invasion and metastasis of NSCLC

Metastasis is one of the major causes of death in lung cancer patients, which is related to a variety of mechanisms and involves multiple steps [44]. Tumor-derived exosomes, as carriers of information transmission, promote metastasis through their direct or indirect roles [13]. Exosomes can promote the formation of the lung cancer microenvironment to increase the invasiveness of tumor cells [45]. Due to the instability of oncogenes, hypoxia, acidosis and inflammatory immune response can promote tumor cells to release more exosomes to form tumor microenvironment [46, 47] which is beneficial to the rapid growth of tumor cells and enhances their ability of invasion. Tumor-derived exosomes are associated with invadopodia that initiates invasion through degradation of the extracellular matrix [48]. Exosomal contents can also promote metastasis and transfer metastatic potential to recipient cells [13]. EMT is the disappearance of the epithelial-like characteristics and gains the phenotype of stromal cells, [49] which is an important process before the metastasis of the tumor cells and also a complex process, including cytoskeleton changes, down-regulation of the expression of adherens junction molecule E-cadherin and so on [50]. It has been reported that several proteins and miRNAs are involved in the EMT [51, 52, 53, 54]. Tumor-derived exosomes have also been reported to be associated with the formation of the pre-metastatic niche [13] that forms at the site of the future metastasis and promotes the growth of disseminated tumor cells [55]. The main sites of NSCLC metastasis are brain, adrenal gland, bone and the liver [44]. Different types of metastatic cancer cells have significant differences in organ tropism [56] which is associated with tumor-derived exosomal integrins [57]. (The major findings of tumor-derived exosomes associated with invasion and metastasis in NSCLC are summarized in Table 2).
Table 2

Major findings of tumor-derived exosomes in NSCLC

Contents

Findings

References

Invasion

exosomal TGF-β and IL-10 may enhance migration ability in vitro under hypoxia

[47]

exosomal vimentin may induce EMT

[51]

exosomal Rab3D which activates AKT/GSK3β signaling may induce EMT

[52]

exosomal miR-23a may affect the changes of EMT related phenotype

[53]

Exosomal miR-302b can inhibit the proliferation and migration of lung cancer cells through the TGFβRII/ERK pathway

[54]

Drug resistance

exosomal VEGF and TGF2β may result in drug resistance

[61, 62]

exosomal proteins and phospholipids components are involved in gefitinib resistance

[63, 64]

exosomes may antagonize the chemotherapeutic effect of cisplatin by upregulating autophagy

[65]

exosomes can regulate the combination of antibody targeting drugs and tumor cells

[71, 72]

Tumor-derived exosomes in the targeted drug resistance

Resistance to chemotherapy, radiotherapy and targeted therapy remains a major obstacle to cancer treatment [30]. Drug resistance is a multifaceted problem. It has already been reported that resistance of targeted therapy and platinum based chemotherapy is associated with microRNAs [58, 59, 60]. Here the authors discuss mechanisms associated with exosomes. (1) Tumor-derived exosomes mediate EMT by transferring related tissue factors (such as VEGF, TGF2β), and thus the tumor cells can resist apoptosis, which usually result in drug resistance [61, 62]. (2) Tumor cells and stromal cells in the tumor microenvironment can secrete exosomes carrying drug-resistant molecules (miRNAs, proteins) which are transferred to enhance the tolerance of the tumor cells to the drug through the interaction of exosomes in the TME (tumor microenvironment) [63, 64, 65]. (3) Tumor-derived exosomes can also mediate the drug efflux by transferring multi-drug resistant (MDR) protein encapsulated drug, thus influencing the drug efficacy. In the development of many malignant tumors, a special transporter system which is MDR-associated ATP-binding cassette transporter (MDR-ABC) is activated to mediate the drug from the intracellular to the extracellular [66]. MDR-ABC is a type of intracellular transporter proteins, which has the same transmembrane domain and is usually located on the membrane of exosomes and multivesicular bodies (MVBs). The chemotherapeutic or targeted therapy drug and its metabolites in the cell can be transferred into the inner body which can aggregate to form MVBs. When the MVBs are fused with the cell membrane, the inner body is released into the extracellular matrix in the form of exosomes and completes the drug efflux [67, 68, 69, 70, 71]. (4) Tumor-derived exosomes can also influence the drug effect by regulating the combination of antibody targeting drugs and tumor cells to enhance the drug resistance of tumor cells [71, 72]. All of these mechanisms associated with exosomes can induce the targeted therapy drug resistance. (The major findings of tumor-derived exosomes associated with drug resistance in NSCLC are summarized in Table 2).

Tumor-derived exosomes as markers in prognosis of NSCLC

Increasingly, studies suggest that exosomal miRNAs and proteins are positively associated with the stage and degree of tumor progression [73], indicating that exosomal components can be used as prognostic markers to improve treatment selection for the patients with NSCLC [74]. For example, Sandfeld-Paulsen et al. investigated exosomes from plasma of 276 non-small-cell lung cancer patients, which were phenotyped by using the Extracellular Vesicle Array. As a result, they found that NY-ESO-1, PLAP, EGFR, Alix and EpCam were correlated to overall survival (OS), which indicated that exosomal membrane-bound proteins were strong prognostic biomarkers in NSCLC [74]. In addition, Liu et al. found that elevated levels of exosomal miR-10b-5p, miR-23b-3p and miR-21-5p were associated with poor overall survival by analyzing 84 plasma exosomal miRNAs in lung adenocarcinoma patients and healthy controls, which suggested that these exosomal miRNAs may also be used as prognostic biomarkers of NSCLC [75]. The downregulation of the miRNA-146-5p indicated a poor progression free survival (PFS) compared to patients with higher exosomal miRNA [76]. All of these indicate that exosomes can be used as non-invasive prognostic biomarkers.

Clinical implications of tumor-derived exosomes in the targeted therapy of NSCLC

Liquid biopsy samples are becoming more frequently used in blood or other body fluids as biomarkers for NSCLC early diagnosis, treatment guidance and drug resistance monitoring [77]. The specificity of the cell types and the accessibility from the body fluids make the exosomes important candidates for the diagnosis and target therapy of tumors [78].

Tumor-derived exosomes as biomarkers for NSCLC diagnosis and targeted therapy guidance

The exosomes secreted by lung cancer cells, which enrich various proteins, such as EGFR, KRAS, claudins and RAB-family proteins, and promote the development of lung cancer, are effective biomarkers for early diagnosis of lung cancer [79] and the basis of targeted therapy. For example, Birgitte et al. used EV array to detect exosomal proteins in NSCLC tissues and normal tissues, and found that markers CD151, CD171 and tetraspanin 8 were higher in patients with cancer of all histological subtypes than patients without cancer [80]. Huang and colleagues carried out immunostaining analysis of exosomes of NSCLC tissues and chronic pneumonia tissues, and found that 80% of the NSCLC specimens were EGFR positive on the surface of the exosomes, while only 2% of the chronic pneumonic tissues were EGFR positive, which suggested that exosomal EGFR protein could be used as a biomarker for differential diagnosis of lung cancer [41] and indicated that gene detection could be further carried out to provide a molecular basis for targeted therapy. Recently, the translocation ALK-EML4 has also been identified inside the exosomes [81], which is a biomarker for response to first generation ALK-TKIs [82]. Vykoukal and colleagues found that the expression of 108 proteins in vesicle preparations of lung adenocarcinoma plasmas was significantly different compared to controls, of which 43 were identified in EVs from lung adenocarcinoma cell lines [83].

MicroRNAs (MiRNAs) are a class of small noncoding RNAs (the length of 18–25 nucleotides), post-transcriptional regulation molecules expressed in many organisms [84]. The expression of miRNAs, like other cancer-associated genes expression, can be altered by chromosomal amplification/deletion, transcription factor activation [85]. It has been found that the miRNAs expression profiles of NSCLC exosomes which are often detected by miRNA-microarray are different from normal tissues. Zhao et al. [86] analyzed the expression of the plasma exosomal miRNAs in the tumor tissues of 150 patients with non-small cell lung cancer, and found that plasma levels of the exosomal hsa-miRNAs (hsa-miR-25, hsa-miR-122, hsa-miR-195, hsa-miR-21 and hsa-miR-125b) were associated with EGFR mutation, which could help to determine whether or not to use targeted therapy drugs and provide a new way to detect NSCLC gene mutations. The miRNAs for adenocarcinoma diagnosis showed an AUC value of 0.936, with a sensitivity of 80.65% and a specificity of 91.67% [87]. Two studies showed that upregulation of miR-1246 and miR-208-a was associated with resistance to radiotherapy and high proliferation of the tumor by targeting the genes p21 and DR5 respectively, which could not only lead to a prognostic biomarker, but also to a new target against NSCLC [88]. It has been possible to detect the rearrangement of EML4-ALK in NSCLC patients by analyzing the exosomal miRNAs in blood and has been proved that the anaplastic lymphoma kinase (ALK)-EML4 translocation inside the exosomes with a specificity of 100% and a sensitivity of 64% [89].

In summary, exosomes are becoming increasingly important in the diagnosis of NSCLC as biomarkers and the molecular basis of NSCLC targeted therapy.

Tumor-derived exosomes as biomarkers for NSCLC targeted therapy resistance

With the increasing understanding of molecular biology and genetics of tumors, the research and clinical application of targeted therapy has become a hot topic, which can improve prognosis and also guide therapeutic decision, thus reducing morbidity and mortality. On average, there are more than 300 mutations in each lung cancer, but only a few of these genes can promote or “drive” the lung tumorigenesis [90], mainly including EGFR_(epidermal growth factor receptor), ALK_(anaplastic lymphoma kinase), c-met and so on [91, 92, 93]. EGFR, also called ErbB1 or HER1, is involved in the signal transduction pathway of cell proliferation and apoptosis, which is a part of the ErbB family of transmembrane receptor tyrosine kinases [94]. The EGFR mutations, first reported in 2004 [95], usually contain in-frame duplications/insertions in exon 20, in-frame deletions (around amino acid residues 747 to 750) in exon 19 and single missense mutations in exon 21_(L858R mutation) [96], and reveal a potential responsiveness of NSCLC to the tyrosine kinase inhibitors [97]. EGFR TKIs improve time to progression, response rates and overall survival, but acquired resistance to EGFR-TKIs is inevitable [98], and thereby tools to predict the risk of drug resistance are necessary to improve the clinical treatment choices. Tumor-derived exosomes can be used as biomarkers to evaluate therapeutic effect of targeted therapy by liquid biopsy. T790 M mutation is found in patients treated with EGFR-TKIs [99], accounting for about 50–60% with acquired resistance to erlotinib or gefitinib [99, 100]. The third generation of EGFR-TKIs includes osimertinib which overcomes T790 M-mediated resistance to EGFR-TKIs [101], but it’s still unable to avoid the targeted therapy drug resistance, and some of the patients develop a new drug resistance mutation C797S [102]. It has been reported that exosomal RNA is used to detect EGFR T790 M and activating EGFR mutations, and the sensitivity is 90% and 98%, respectively [103]. So it’s possible to identify targeted therapy drug resistance in the tumor-derived exosomes. In addition, Choi et al. [63]. identified PC9R cells with rich EV proteins were resistant to gefitinib due to EGFR T790 M mutation by Nano-LC–MS/MS analysis and would help to develop new diagnostic strategies to predict and assess the drug resistance of gefitinib. Chromosome rearrangements of ALK are detected in the NSCLC of 3–7%, which indicates a response to first generation ALK-TKIs (such as crizotinib). However, most patients develop resistance to this therapy [104]. L1196 M and G1269A are identified as secondary mutation, accounting for resistance to ALK-TKIs [104, 105]. This acquired drug resistance may be predicted by detecting exosomes.

The potential value of tumor-derived exosomes in the targeted therapy of NSCLC

Studies have found that research based on exosomes and related components can provide new inspiration for the precision treatment of NSCLC.

Exosomes have been developed as drug delivery vehicles for a variety of drugs, such as small molecular drugs, nucleic acid proteins and other drugs for cancer treatment, with low immunogenicity and toxicity [106, 107]. Lai et al. used electroporation or lipofection to transfect the drugs of interest directly into the exosomes or transfer the genes that encode for the RNA/protein of interest into exosome-secreting cells [108]. Mendt and colleagues established a standard operating procedure to generate engineered exosomes which had the ability to target oncogenic Kras (iExosomes), and was confirmed to suppress oncogenic Kras and increase the survival of mouse models with pancreatic cancer, which laid the foundation for exosomes in the targeted therapy of NSCLC [109]. Exosomes can be targetable to specific tissues, resistant to metabolic processes and membrane-permeable [110], which have a wide application prospect in the targeted therapy of NSCLC.

Exosomes play an important role in tumor development, which indicates reducing the contents of exosomes can help the targeted therapy of NSCLC. Exosomes may also serve as a direct target for NSCLC. Data shows that the prevention of exosomes production can inhibit tumorigenesis and a series of methods have been suggested to reduce the contents of exosomes [110]: (1) Blood purification: Aethlon Medical designed a blood filtration therapy which could capture a large number of antibodies and other similar substances, such as aptamers, protein ligands, and exosomes to realize the new treatment of NSCLC [111]. Other studies have shown that the use of hollow fiber filtration technology to remove exosomes from the patient’s blood can minimize the immune tolerance caused by the exosomes [112]. (2) Change the local pH of the tumor: In addition to blood purification, proton pump inhibitors (PPIs) can also improve the low pH of cells by PPI pretreatment in vivo to reduce the contents of tumor-derived exosomes in the plasma, so PPI may likely be an effective method to inhibit the secretion of exosomes in NSCLC [113]. (3) Drug usage: For example, Fabbri et al. [114]. found that the use of GW4869, a neutral sphingomyelase inhibitor (regulates ceramide biosynthesis, promotes exosomes inward budding), could inhibit the production of exosomes in mice and reduce the metastasis of lung cancer. Some studies directly target exosomes as a drug target. For example, amiloride can inhibit the synthesis and secretion of exosomes [115], and diannexin can impede the absorption of exosomes by receptor cells [116]. (4) Interfere with signal pathway: some studies have shown that interference with the signal pathway associated with production or secretion of tumor-derived exosomes can inhibit the exosomes secretion. Ostrowski and colleagues found that knockout Rab27 or its effector (SYTL4 and EXPH5) could inhibit the secretion of exosomes in HeLa cells [24]. It may be useful for inhibiting the secretion of exosomes in NSCLC. It has already been proved that ISGylation as a novel ubiquitin-like modifier can control exosomes production [117] and syndecan-syntenin-ALIX plays a key role in the biogenesis of exosomes [118], which can also be targeted in NSCLC.

The diversity of exosomes components and functions associated with NSCLC provides multiple potential therapeutic targets for the treatment of NSCLC. Yang et al. found that the promotion of the expression of let-7 in exosomes was a potential target for the treatment of NSCLC because of its high tumor suppressor effect, great clinical significance and tissue specificity [119]. Zhang et al. [120]. identified that exosomes separated from H460 cells with restoration of LKB1 (liver kinase B1) had a higher ability in lung cancer cell migration, which could be a novel target. Nao et al. [121]. developed a new strategy of antibody therapy with anti-CD9 or anti-CD63 to target on tumor-derived exosomes and inhibit metastasis of breast cancer in mouse models, which laid the foundation for targeted therapy of NSCLC. Lung cancer cells can secrete survivin through exosomes to inhibit the apoptosis of lung cancer cells and promote the growth of lung cancer cells, so the use of survivin gene negative mutant (Survivin-D53A) can promote the apoptosis of NSCLC cells and may become a potential gene therapy drug [122, 123, 124]. Previously described exosomal miR-302b also provided a potential target for the treatment of NSCLC [54]. The exosomes membrane can contain specific tumor antigen through gene transformation, which has a certain target function and can be used for the treatment of NSCLC [125, 126].

In summary, studies on the treatment of lung cancer-related exosomes will provide a new idea for exploring precision treatment of NSCLC. (These potential values are summarized in Table 3).
Table 3

Tumor-derived exosomes in the targeted therapy of NSCLC

Potential value

Methods

References

A tool for drug delivery

Use electroporation or lipofection

[106, 107, 108, 109, 110]

A direct target for reducing the content

Blood purification: ADAPT, hollow fiber filtration technology

Change the local pH of the tumor: PPIs

Drug usage: GW4869, amiloride, diannexin

Interfere with signal pathway: knockout Rab27, SYTL4

,EXPH5, ISGylation and syndecan-syntenin-ALIX

[24, 110, 111, 112, 113, 114, 115, 116, 117, 118]

Other targets

let-7, LKB1, CD9, CD63, surviving, miR-302b

[54, 119, 120, 121, 122, 123, 124, 125, 126]

Conclusion

In 2006, WHO officially identified lung cancer as a chronic controlled disease whose occurrence and development was a multidirectional, multistep complex network process. Liquid biopsy for tumor-derived exosomes has the advantages of noninvasive and real-time monitoring, which provides a new reference for precision medical and individualized treatment, and develops a new method for early diagnosis, prognosis evaluation, drug delivery and targeted therapy. At present, the application of exosomes in the diagnosis and treatment of NSCLC is still in their initial stage. In the future, further study in exosomes, including biogenesis, secretion, interaction with target cells and the roles of exosomal components may improve applications to medical treatment and improve the survival rate of NSCLC patients. A variety of problems remain to be overcame: (1) The specific mechanism of exosomes as an important part of the tumor microenvironment in the evolution of the NSCLC is not yet clear; (2) The sensitivity and specificity of exosomes application in the diagnosis and treatment of NSCLC still need improvement; (3) The acquisition of high purity exosomes is still an issue due to technical limitation and high cost; (4) The quantification, purification and preservation of exosomes has not yet been standardized; (5) The side effects of exosomes used in the targeted therapy cannot be completely determined. All of these problems restrict the application of exosomes in NSCLC. These reviews synthetically expound the multi-faceted nature of exosomes and potential value in the targeted therapy of NSCLC.

Notes

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundations of China (No: 81773218, 81472773, 81703009 and 81272566).

Availability of data and materials

Not applicable.

Authors’ contributions

All authors contributed to the conception and design of the manuscript, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRefGoogle Scholar
  2. 2.
    Fan H, Shao ZY, Xiao YY, Xie ZH, Chen W, Xie H, Qin GY, Zhao NQ. Incidence and survival of non-small cell lung cancer in Shanghai_a population-based cohort study. BMJ Open. 2015;5(12):e009419.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer_ molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165–72.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975–2013, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Bethesda: National Cancer Institute; 2016. Available at: http://seer.cancer.gov/csr/1975_2013/. Accessed 3 Mar 2017.
  5. 5.
    Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. J Natl Compr Cancer Netw. 2014;12(12):1738–61.CrossRefGoogle Scholar
  6. 6.
    Lee SW, Choi EK, Chung WK, Shin KH, Ahn SD, Kim JH, Kim SW, Suh C, Lee JS, Kim WS, Kim DS, Kim DK, Park SI, Sohn KH. Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC). Lung Cancer. 2002;37(1):65–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, Bergström S, Hanna L. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK_ a population-based study, 2004–2007. Thorax. 2013;68(6):551–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Kumarakulasinghe NB, van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stagenon-small cell lung cancer (NSCLC). Respirology. 2015;20(3):370–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015;16(7):e342–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Levy B, Hu ZI, Cordova KN, Close S, Lee K, Becker D. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer. Oncologist. 2016;21(9):1121–30.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Molina-Vila MA, Mayo-de-Las-Casas C, Giménez-Capitán A, Jordana-Ariza N, Garzón M, Balada A, Villatoro S, Teixidó C, García-Peláez B, Aguado C, Catalán MJ, Campos R, Pérez-Rosado A, Bertran-Alamillo J. Liquid Biopsy in Non-Small Cell Lung Cancer. Front Med (Lausanne). 2016;3:69.Google Scholar
  12. 12.
    Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011;2:180.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM. Exosome mediated communication within the tumor microenvironment. J Control Release. 2015;219:278–94.CrossRefGoogle Scholar
  14. 14.
    Sharma S, Zuñiga F, Rice GE, Perrin LC, Hooper JD, Salomon C. Tumor-derived exosomes in ovarian cancer – liquid biopsies for early detection and real-time monitoring of cancer progression. Oncotarget. 2017;8(61):104687–703.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Simons M, Raposo G. Exosomes—vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21(4):575–81.CrossRefGoogle Scholar
  16. 16.
    Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferring receptor in vesicular form in sheep reticulocytes. J Cell Biol. 1985;101(3):942–8.CrossRefGoogle Scholar
  17. 17.
    Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999;147(3):599–610.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, Hivroz C. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. Immunol. 2002;168(7):3235–41.CrossRefGoogle Scholar
  19. 19.
    Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. Exp Med. 1996;183(3):1161–72.CrossRefGoogle Scholar
  20. 20.
    Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7(3):297–303.CrossRefPubMedGoogle Scholar
  21. 21.
    Conde-Vancells J, Rodriguez-Suarez E, Embade N, Gil D, Matthiesen R, Valle M, Elortza F, Lu SC, Mato JM, Falcon-Perez JM. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. Proteome Res. 2008;7(2):5157–66.CrossRefGoogle Scholar
  22. 22.
    Mittelbrunn M, Sanchez-Madrid F. Intercellular communication: diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol. 2012;13:328–35.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhou J, Li XL, Chen ZR, Chng WJ. Tumor-derived exosomes in colorectal cancer progression and their clinical applications. Oncotarget. 2017;8(59):100781–90.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, Goud B, Benaroch P, Hacohen N, Fukuda M, Desnos C, Seabra MC, Darchen F, Amigorena S, Moita LF, Thery C. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010; 12(1):19–30; sup pp 1–13.CrossRefPubMedGoogle Scholar
  25. 25.
    Greening DW, Gopal SK, Xu R, Simpson RJ, Chen W. Exosomes and their roles in immune regulation and cancer. Semin Cell Dev Biol. 2015;40:72–81.CrossRefPubMedGoogle Scholar
  26. 26.
    Theresa L. Whiteside. Exosomes and tumor-mediated immune suppression. J Clin Invest. 2016;126(4):1216–23.CrossRefGoogle Scholar
  27. 27.
    Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016;126(4):1208–15.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Frydrychowicz M, Kolecka-Bednarczyk A, Madejczyk M, Yasar S, Dworacki G. Exosomes-Structure, Biogenesis and Biological Role in Non-Small-Cell Lung Cancer. Scand J Immunol. 2015;81(1):2–10.CrossRefPubMedGoogle Scholar
  29. 29.
    Blackwell RH, Foreman KE, Gupta GN. The Role of Cancer-Derived Exosomes in Tumorigenicity & Epithelial-to-Mesenchymal Transition. Cancers (Basel). 2017; 9(8).CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Azmi AS, Bao B, Sarkar FH. Exosomes in Cancer Development, Metastasis and Drug Resistance: A Comprehensive Review. Cancer Metastasis Rev. 2013;32(3–4):623–42.CrossRefGoogle Scholar
  31. 31.
    Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015;8:83.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, Marini JC, Tudawe T, Seviour EG, San Lucas FA, Alvarez H, Gupta S, Maiti SN, Cooper L, Peehl D, Ram PT, Maitra A, Nagrath D. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. elife. 2016;5:e10250.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Eldridge L, Moldobaeva A, Zhong Q, Jenkins J, Snyder M, Brown RH, Mitzner W, Wagner EM. Bronchial artery angiogenesis drives lung tumor growth. Cancer Res. 2016;76(20):5962–9.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R, Wymant J, Jones AT, Kynaston H, Mason MD, Tabi Z, Clayton A. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene. 2015;34(3):290–302.CrossRefPubMedGoogle Scholar
  35. 35.
    Hsu YL, Hung JY, Chang WA, Lin YS, Pan YC, Tsai PH, Wu CY, Kuo PL. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017;36(34):4929–42.CrossRefPubMedGoogle Scholar
  36. 36.
    Liu Y, Luo F, Wang B, Li H, Xu Y, Liu X, Shi L, Lu X, Xu W, Lu L, Qin Y, Xiang Q, Liu Q. STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 2016;370(1):125–35.CrossRefPubMedGoogle Scholar
  37. 37.
    Cui H, Seubert B, Stahl E, Dietz H, Reuning U, Moreno-Leon L, Ilie M, Hofman P, Nagase H, Mari B, Krüger A. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene. 2015;34(28):3640–50.CrossRefPubMedGoogle Scholar
  38. 38.
    Li X, Wang S, Zhu R, Li H, Han Q, Zhao RC. Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NFκB-TLR signaling pathway. J Hematol Oncol. 2016;9:42.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Ridder K, Sevko A, Heide J, Dams M, Rupp AK, Macas J, Starmann J, Tjwa M, Plate KH, Sültmann H, Altevogt P, Umansky V, Momma S. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology. 2015;4(6):e1008371.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010;5(7):e11469.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Huang SH, Li Y, Zhang J, Rong J, Ye S. Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells. Cancer Investig. 2013;31(5):330–5.CrossRefGoogle Scholar
  42. 42.
    Liu Y, Gu Y, Cao X. The exosomes in tumor immunity. Oncoimmunology. 2015;4(9):e1027472.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Rébé C, Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120(2):457–71.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.CrossRefGoogle Scholar
  45. 45.
    Fujita Y, Kosaka N, Araya J, Kuwano K, Ochiya T. Extracellular vesicles in lung microenvironment and pathogenesis. Trends Mol Med. 2015;21(9):533–42.CrossRefPubMedGoogle Scholar
  46. 46.
    King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2012;12:421.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Wang Y, Yi J, Chen X, Zhang Y, Xu M, Yang Z. The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-β and IL-10. Oncol Lett. 2016;11(2):1527–30.CrossRefPubMedGoogle Scholar
  48. 48.
    Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, Grega-Larson N, Tyska MJ, Weaver AM. Exosome secretion is enhanced by invadopodia and drives invasive behavior. Cell Rep. 2013;5(5):1159–68.CrossRefPubMedGoogle Scholar
  49. 49.
    Vella LJ. The emerging role of exosomes in epithelial-mesenchymal-transition in cancer. Front Oncol. 2014;4:361.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, Graner M, Frederick B, Agarwal R, Deep G. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog. 2015;54(7):554–65.CrossRefPubMedGoogle Scholar
  51. 51.
    Rahman MA, Barger JF, Lovat F, Gao M, Otterson GA, Nana-Sinkam P. Lung cancer exosomes as drivers of epithelial mesenchymal transition. Oncotarget. 2016;7(34):54852–66.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Yang J, Liu W, Lu X, Fu Y, Li L, Luo Y. High expression of small GTPase Rab3D promotes cancer progression and metastasis. Oncotarget. 2015;6(13):11125–38.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Kim J, Kim TY, Lee MS, Mun JY, Ihm C, Kim SA. Exosome cargo reflects TGF-beta1-mediated epithelial-to-mesenchymal transition (EMT) status in A549 human lung adenocarcinoma cells. Biochem Biophys Res Commun. 2016;478(2):643–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Li J, Yu J, Zhang H, Wang B, Guo H, Bai J, Wang J, Dong Y, Zhao Y, Wang Y. Exosomes-Derived MiR-302b Suppresses Lung Cancer Cell Proliferation and Migration via TGFβRII Inhibition. Cell Physiol Biochem. 2016;38(5):1715–26.CrossRefPubMedGoogle Scholar
  55. 55.
    Alderton GK. Metastasis. Exosomes drive premetastatic niche formation. Nat Rev Cancer. 2012;12(7):447.CrossRefGoogle Scholar
  56. 56.
    Obenauf AC, Massagué J. Surviving at a distance: organ specific metastasis. Trends Cancer. 2015;1(1):76–91.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–35.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Zang H, Peng J, Wang W, Fan S. Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer. J Cancer. 2017;8(18):3856–61.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Zang H, Wang W, Fan S. The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79(2):227–31.CrossRefPubMedGoogle Scholar
  60. 60.
    Yu S, Cao H, Shen B, Feng J. Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget. 2015;6(35):37151–68.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Acloque H, Thiery JP, Nieto MA. The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. EMBO Rep. 2008;9(4):322–6.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Andarawewa KL, Erickson AC, Chou WS, Costes SV, Gascard P, Mott JD, Bissell MJ, Barcellos-Hoff MH. Ionizing Radiation Predisposes Nonmalignant Human Mammary Epithelial Cells to Undergo Transforming Growth Factor B–Induced Epithelial to Mesenchymal Transition. Cancer Res. 2007;67(18):8662–70.CrossRefPubMedGoogle Scholar
  63. 63.
    Choi DY, You S, Jung JH, Lee JC, Rho JK, Lee KY, Freeman MR, Kim KP, Kim J. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. Proteomics. 2014;14(16):1845–56.CrossRefPubMedGoogle Scholar
  64. 64.
    Jung JH, Lee MY, Choi DY, Lee JW, You S, Lee KY, Kim J, Kim KP. Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells. Proteomics. 2015;15(4):824–35.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Li XQ, Liu JT, Fan LL, Liu Y, Cheng L, Wang F, Yu HQ, Gao J, Wei W, Wang H, Sun GP. Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy. Oncotarget. 2016;7(17):24585–95.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci. 2004;61(6):682–99.CrossRefPubMedGoogle Scholar
  67. 67.
    Lee CH. Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol. 2010;596:325–40.CrossRefPubMedGoogle Scholar
  68. 68.
    Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11(4):265–83.CrossRefPubMedGoogle Scholar
  69. 69.
    Hegedus C, Ozvegy-Laczka C, Szakács G, Sarkadi B. Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors? Curr Cancer Drug Targets. 2009;9(3):252–72.CrossRefPubMedGoogle Scholar
  70. 70.
    Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012;227(2):658–67.CrossRefGoogle Scholar
  72. 72.
    Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, Weinhage T, Menck K, Hupfeld T, Koch R, Trümper L, Wulf GG. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A. 2011;108(37):15336–41.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Wang Z, Chen JQ, Liu JL, Tian L. Exosomes in tumor microenvironment: novel transporters and biomarkers. J Transl Med. 2016;14(1):297.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Sandfeld-Paulsen B, Aggerholm-Pedersen N, Bæk R, Jakobsen KR, Meldgaard P, Folkersen BH, Rasmussen TR, Varming K, Jørgensen MM, Sorensen BS. Exosomal proteins as prognostic biomarkers in non-small cell lung cancer. Mol Oncol. 2016;10(10):1595–602.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Liu Q, Yu Z, Yuan S, Xie W, Li C, Hu Z, Xiang Y, Wu N, Wu L, Bai L, Li Y. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer. Oncotarget. 2017;8(8):13048–58.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Yuwen DL, Sheng BB, Liu J, Wenyu W, Shu YQ. MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017;21(11):2650–8.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Tang Y, Qiao G, Xu E, Xuan Y, Liao M, Yin G. Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer. Onco Targets Ther. 2017;10:4527–34.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Zhao L, Liu W, Xiao J, Cao B. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance. Cancer Lett. 2015;356(2 Pt B):339–46.CrossRefPubMedGoogle Scholar
  79. 79.
    Clark DJ, Fondrie WE, Yang A, Mao L. Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes. Proteomics. 2016;133:161–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Sandfeld-Paulsen B, Jakobsen KR, Bæk R, Folkersen BH, Rasmussen TR, Meldgaard P, Varming K, Jørgensen MM, Sorensen BS. Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. J Thorac Oncol. 2016;11(10):1701–10.CrossRefPubMedGoogle Scholar
  81. 81.
    Brinkmann K, Enderle D, Koestler T, Bentink S, Emenegger J, Spiel A, Mueller R, Vincent O, Skog J, Noerholm M. Abstract 545: Plasma-based diagnostics for detection of EML4-ALK fusion transcripts in NSCLC patients. Cancer Res. 2015;75:545.CrossRefGoogle Scholar
  82. 82.
    Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Vykoukal J, Sun N, Aguilar-Bonavides C, Katayama H, Tanaka I, Fahrmann JF, Capello M, Fujimoto J, Aguilar M, Wistuba II, Taguchi A, Ostrin EJ, Hanash SM. Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget. 2017;8(56):95466–80.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75–93.CrossRefPubMedGoogle Scholar
  85. 85.
    Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.CrossRefPubMedGoogle Scholar
  86. 86.
    Zhao Q, Cao J, Wu YC, Liu X, Han J, Huang XC, Jiang LH, Hou XX, Mao WM, Ling ZQ. Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers. Am J Cancer Res. 2015; 15; 5(5):1692–705. eCollection 2015.Google Scholar
  87. 87.
    Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, Liu L, Lin B, Su H, Zhao L, Su M, Pan H, Shen L, Xie D, Xie C. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing. Clin Cancer Res. 2017;23(17):5311–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Reclusa P, Taverna S, Pucci M, Durendez E, Calabuig S, Manca P, Serrano MJ, Sober L, Pauwels P, Russo A, Rolfo C. Exosomes as diagnostic and predictive biomarkers in lung cancer. J Thorac Dis. 2017;9(Suppl 13):S1373–82.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Rolfo C, Laes JF, Reclusa P, Valentino A, Peeters M. P2.01-093 Exo-ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients. J Thorac Oncol. 2017;12(1):S844–5.CrossRefGoogle Scholar
  90. 90.
    Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr KKW. Cancer genome landscapes. Science. 2013;339(6127):1546–58.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Steuer CE, Ramalingam SS. Targeting EGFR in lung cancer: Lessons learned and future perspectives. Mol Asp Med. 2015;45:67–73.CrossRefGoogle Scholar
  92. 92.
    Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105–11.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Gelsomino F, Rossi G, Tiseo M. MET and Small-Cell Lung Cancer. Cancers (Basel). 2014;6(4):2100–15.CrossRefGoogle Scholar
  94. 94.
    Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81.CrossRefPubMedGoogle Scholar
  95. 95.
    Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–46.CrossRefGoogle Scholar
  97. 97.
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Wu SG, Shih JY. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–92.CrossRefPubMedGoogle Scholar
  100. 100.
    Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF, Shih JY. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016;7(11):12404–13.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–61.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–2.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Krug AK, Enderle D, Karlovich C, et al. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann Oncol. 2018 Mar 1;29(3):700–6.CrossRefPubMedGoogle Scholar
  104. 104.
    Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662–73.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472–82.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396–405.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Harding CV, Heuser JE, Stahl PD. Exosomes: looking back three decades and into the future. J Cell Biol. 2013;200(4):367–71.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Lai RC, Yeo RW, Tan KH, Lim SK. Exosomes for drug delivery - a novel application for the mesenchymal stem cell. Biotechnol Adv. 2013;31:543–51.CrossRefPubMedGoogle Scholar
  109. 109.
    Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, Marszalek JR, Maitra A, Yee C, Rezvani K, Shpall E, LeBleu VS, Kalluri R. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018;3(8).Google Scholar
  110. 110.
    Tickner JA, Urquhart AJ, Stephenson SA, Richard DJ, O'Byrne KJ. Functions and therapeutic roles of exosomes in cancer. Front Oncol. 2014;4:127.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012;10(1):134.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J, Bogin V, Minev BR, Min WP, Tullis RH. Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med. 2008;6:37.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, D'Ilio S, Lugini L, Violante N, Azzarito T, Majorani C, Brambilla D, Fais S. Exosome release and low PH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One. 2014;9(2):e88193.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H, Caligiuri MA, Nana-Sinkam P, Perrotti D, Croce CM. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012;109(31):E2110–6.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Savina A, Furlán M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 2003;278(22):20083–90.CrossRefGoogle Scholar
  116. 116.
    Combes V, Latham SL, Wen B, Allison AC, Grau GE. Diannexin down-modulates tnf-induced endothelial microparticle release by blocking membrane budding process. Int J Innov Med Health Sci. 2016;7:1–11.PubMedPubMedCentralGoogle Scholar
  117. 117.
    Villarroya-Beltri C, Baixauli F, Mittelbrunn M, Fernández-Delgado I, Torralba D, Moreno-Gonzalo O, Baldanta S, Enrich C, Guerra S, Sánchez-Madrid F. ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins. Nat Commun. 2016;7:13588.CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E, Zimmermann P, David G. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012;14(7):677–85.CrossRefPubMedGoogle Scholar
  119. 119.
    Yang G, Zhang W, Yu C, Ren J, An Z. MicroRNA let-7: Regulation, single nucleotide polymorphism, and therapy in lung cancer. J Cancer Res Ther. 2015;11(Suppl 1):C1–6.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Zhang C, Xiao X, Chen M, Aldharee H, Chen Y, Long W. Liver kinase B1 restoration promotes exosome secretion and motility of lung cancer cells. Oncol Rep. 2018;39(1):376–82.CrossRefPubMedGoogle Scholar
  121. 121.
    Nishida-Aok N, Tominaga N, Takeshita F, Sonoda H, Yoshioka Y, Ochiya T. Disruption of Circulating Extracellular Vesicles as a Novel Therapeutic Strategy against Cancer Metastasis. Mol Ther. 2017;25(1):181–91.CrossRefGoogle Scholar
  122. 122.
    Zhu DE, Höti N, Song Z, Jin L, Wu Z, Wu Q, Wu M. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model. Cancer Gene Ther. 2006;13(8):762–70.CrossRefPubMedGoogle Scholar
  123. 123.
    Galbo PM, Jr CMJ, Figel S, Maguire O, Qiu J, Wiltsie L, Minderman H, Fenstermaker RA. Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget. 2017;8(70):114722–35.CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    H T, Liu S, Zhang J, Zhang S, Cheng L, Li C, Zhang X, Dail L, Fan P, Dai L, Yan N, Wang R, Wei Y, Deng H. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin. J Biomed Nanotechnol. 2012;8(4):633–41.CrossRefGoogle Scholar
  125. 125.
    L A-E, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–5.CrossRefGoogle Scholar
  126. 126.
    Ohno SI, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, Fujita K, Mizutani T, Ohgi T, Ochiya T, Gotoh N, Kuroda M. Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. Mol Ther. 2013;21:185.CrossRefGoogle Scholar
  127. 127.
    Zeringer E, Barta T, Li M, Vlassov AV. Strategies for Isolation of Exosomes. Cold Spring Harb Protoc. 2015;2015(4):319–23.CrossRefPubMedGoogle Scholar
  128. 128.
    Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006; Chapter 3: Unit 3.22.Google Scholar
  129. 129.
    Momen-Heravi F, Balaj L, Alian S, Mantel PY, Halleck AE, Trachtenberg AJ, Soria CE, Oquin S, Bonebreak CM, Saracoglu E, Skog J, Kuo WP. Current methods for the isolation of extracellular vesicles. Biol Chem. 2013;394(10):1253–62.CrossRefPubMedGoogle Scholar
  130. 130.
    Enderle D, Spiel A, Coticchia CM, Berghoff E, Mueller R, Schlumpberger M, Sprenger-Haussels M, Shaffer JM, Lader E, Skog J, Noerholm M. Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method. PLoS One. 2015;10(8):e0136133.CrossRefPubMedPubMedCentralGoogle Scholar
  131. 131.
    Baranyai T, Herczeg K, Onódi Z, Voszka I, Módos K, Marton N, Nagy G, Mäger I, Wood MJ, El Andaloussi S, Pálinkás Z, Kumar V, Nagy P, Kittel Á, Buzás EI, Ferdinandy P, Giricz Z. Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods. PLoS One. 2015;10(12):e0145686.CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    Muller L, Hong CS, Stolz DB, Watkins SC, Whiteside TL. Isolation of biologically-active exosomes from human plasma. J Immunol Methods. 2014;41:55–65.CrossRefGoogle Scholar
  133. 133.
    Gardiner C, Ferreira YJ, Dragovic RA, Redman CW, Sargent IL. Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. J Extracell Vesicles. 2013;2.CrossRefGoogle Scholar
  134. 134.
    Coscia C, Parolini I, Sanchez M, Biffoni M, Boussadia Z, Zanetti C, Fiani ML, Sargiacomo M. Generation, Quantification, and Tracing of Metabolically Labeled Fluorescent Exosomes. Methods Mol Biol. 2016;1448:217–35.CrossRefPubMedGoogle Scholar
  135. 135.
    Higginbotham JN, Zhang Q, Jeppesen DK, Scott AM, Manning HC, Ochieng J, Franklin JL, Coffey RJ. Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting. J Extracell Vesicles. 2016;5:29254.CrossRefPubMedGoogle Scholar
  136. 136.
    Kreimer S, Belov AM, Ghiran I, Murthy SK, Frank DA, Ivanov AR. Mass-spectrometry-based molecular characterization of extracellular vesicles: lipidomics and proteomics. J Proteome Res. 2015;14(6):2367–84.CrossRefPubMedGoogle Scholar
  137. 137.
    Bastos-Amador P, Royo F, Gonzalez E, Conde-Vancells J, Palomo-Diez L, Borras FE, Falcon-Perez JM. Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability. J Proteome. 2012;75(12):3574–84.CrossRefGoogle Scholar
  138. 138.
    Selmaj I, Cichalewska M, Namiecinska M, Galazka G, Horzelski W, Selmaj KW, Mycko MP. Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. Ann Neurol. 2017;81(5):703–17.CrossRefPubMedGoogle Scholar
  139. 139.
    Vallabhajosyula P, Korutla L, Habertheuer A, Yu M, Rostami S, Yuan CX, Reddy S, Liu C, Korutla V, Koeberlein B, Trofe-Clark J, Rickels MR, Naji A. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue. J Clin Invest. 2017;127(4):1375–91.CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    Chen Y, Buyel JJ, Hanssen MJ, Siegel F, Pan R, Naumann J, Schell M, van der Lans A, Schlein C, Froehlich H, Heeren J, Virtanen KA, van Marken Lichtenbelt W, Pfeifer A. Exosomal microRNA miR-92a concentration in serum reflects human brown fat activity. Nat Commun. 2016;7:11420.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s). 2018

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Hongmei Zheng
    • 1
  • Yuting Zhan
    • 1
  • Sile Liu
    • 1
  • Junmi Lu
    • 1
  • Jiadi Luo
    • 1
  • Juan Feng
    • 1
  • Songqing Fan
    • 1
  1. 1.Department of PathologyThe Second Xiangya Hospital, Central South UniversityChangshaChina

Personalised recommendations